Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33rd Annual Healthcare Conference on March 14th, 2023 at 9:20 a.m. ET. Ms.

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gamida Cell (GMDA) Upgraded to Buy: Here's Why

BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”). Pursuant to the loan agreement, Gamida Cell's wholly-owned subsidiary, as borrower, will draw down $25 million from the facility with a maturity date of December 12, 2024.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences:

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company's Biologics License Application (BLA) for omidubicel, the company's advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant.

Gamida Cell Provides Regulatory Update on Omidubicel

Gamida Cell Ltd. (NASDAQ:GMDA ) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Abigail Jenkins - President & CEO Ronit Simantov - CMO & Chief Scientific Officer Michele Korfin - COO & Chief Commercial Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Jonathan Miller - Evercore ISI Gilbert Blum - Needham Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by.

Gamida Cell Ltd. (GMDA)Q3 2022 Earnings Call Transcript

BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022. Net loss for the third quarter of 2022 was $17.8 million, compared to a net loss of $23.2 million in the third quarter of 2021. As of September 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $61.3 million.

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be held October 11-13, 2022 in Carlsbad, California and livestreamed globally. Ms. Korfin will discuss 2022 catalysts an

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of new long term follow-up data and health-related quality of life scores of patients treated with omidubicel at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO), being held in Houston, Texas. “These data reinforce our commitment to advance transform

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), pursuant to which Highbridge has committed to provide a $25 million senior secured, convertible term loan (the “term loan”). The Commitment Letter does not repres

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds of $20 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Ce

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subje

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that Abigail “Abbey” L. Jenkins, MS, has joined as President & CEO. Ms. Jenkins has also been appointed to Gamida Cell's Board of Directors. Ms. Jenkins succeeds Julian Adams, Ph.D., who is retiring in accordance with planned succession and will continue to serve on the company

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

BOSTON--(BUSINESS WIRE)-- #BloodCancerAwarenessMonth--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of data supporting the potential of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant at the 2022 Cord Blood Connect Meeting, being held in South Beach, Florida. “We continue to be encouraged by the gro

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Gamida Cell Ltd. (NASDAQ:GMDA ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Julian Adams - CEO Ronit Simantov - CMO & Chief Scientific Officer Michele Korfin - COO & Chief Commercial Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Jonathan Miller - Evercore Gilbert Blum - Needham Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen and I will be your Operator for today's call.

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022. Net loss for the second quarter of 2022 was $18.6 million, compared to a net loss of $23.6 million in the second quarter of 2021. As of June 30, 2022, Gamida Cell had total cash, cash equivalents and inve

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525). “We are excited to further advance the development of GDA-201, a NAM

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, a

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY. Management will discuss 2022 catalysts and potential milestones including the U.S. market opportunity for omi

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

News for Gamida Cell Ltd Stock (GMDA)